Blow for HSP, 2013 View Withdrawn - Analyst Blog
19 Fevereiro 2013 - 10:50AM
Zacks
Hospira Inc.’s
(HSP) shares fell significantly following the import ban imposed by
the US Food and Drug Administration (FDA) on some of the company’s
offerings. Hospira withdrew its guidance for 2013 following the FDA
decision.
We remind investors that in Nov 2012, the FDA had issued a
directive prohibiting the Hospira from importing Symbiq medication
infusion pumps, manufactured at its Costa Rica facility, into the
US. However, a few days back the FDA dealt a more damaging blow to
Hospira when it expanded the import ban. Following the fresh
directive, Hospira is also prohibited from importing Plum, GemStar
and LifeCare PCA infusion pumps, manufactured in Costa Rica, into
the US. Hospira stated that it intends to support the repair and
service of the affected pumps to existing customers.
Hospira expects the expansion of the import ban to adversely impact
its 2013 net sales by $50–$100 million. The expectation is based on
the assumption that the ban will stay throughout 2013. The company
also expects the FDA’s action to hurt its adjusted per share
earnings guidance of $2.05 to $2.20 (issued while releasing
its fourth quarter and full year 2012 earnings results
) by 5–15 cents per share. Hospira intends to issue a new
guidance for 2013 while releasing its earnings results for the
first quarter of 2013 later this year.
Apart from the issue related to the infusion pumps, Hospira is
facing many other challenges. The ongoing manufacturing issues at
its Rocky Mountain facility have hurt the company’s earnings over
the last few quarters. The issue, until resolved, will remain a
major overhang on the stock. Manufacturing issues at Hospira’s
other facilities, such as at Lake Forest, McPherson, Austin and
IKKT are further challenges for this global specialty
pharmaceutical and medication delivery company.
Hospira carries a Zacks Rank #3 (Hold). Favorably placed stocks in
the medical sector include Covidien plc (COV),
Medtronic, Inc. (MDT) and Edwards
Lifesciences Corporation (EW). All these stocks carry a
Zacks Rank #2 (Buy).
COVIDIEN PLC (COV): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
HOSPIRA INC (HSP): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira